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bstract
he American College of Cardiology Foundation (ACCF)
nd the American Society of Echocardiography (ASE),
ogether with key specialty and subspecialty societies, con-
ucted an appropriateness review for transthoracic and
ransesophageal echocardiography (TTE/TEE). This re-
iew assesses the risks and benefits of TTE and/or TEE for
everal indications or clinical scenarios and scored them
ased on a scale of 1 to 9. The upper range (7 to 9) implies
hat the test is generally acceptable and is a reasonable
pproach, and the lower range (1 to 3) implies that the test
s generally not acceptable and is not a reasonable approach.
he midrange (4 to 6) indicates a clinical scenario for which
he indication for an echocardiogram is uncertain.
The indications for this review were drawn from common
pplications or anticipated uses as well as current clinical
ractice guidelines. Use of TTE/TEE for initial evaluation
f structure and function was viewed favorably, while
outine repeat testing and general screening uses in certain
linical scenarios were viewed less favorably. It is anticipated
hat these results will have a significant impact on physician
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nd will help guide future research.
reface
n an effort to respond to the need for the rational use of
maging services in the delivery of high quality care, the
merican College of Cardiology Foundation (ACCF) has
ndertaken a process to determine the appropriateness of
ardiovascular imaging for selected patient indications.
Appropriateness criteria publications reflect an ongoing
ffort by the College to critically and systematically create,
eview, and categorize clinical situations where diagnostic
ests and procedures are utilized by physicians caring for
atients with cardiovascular diseases. The process is based
n the current understanding of the technical capabilities of
he imaging modalities examined. Although not intended to
e entirely comprehensive, the indications are meant to
dentify common scenarios encompassing the majority of
ontemporary practice. Given the breadth of information
hey convey, the indications do not directly correspond to
he classification system of the International Classification
f Diseases, ninth revision (ICD-9).
The ACCF believes that a careful blending of a broad
ange of clinical experiences and available evidence-based
nformation will help guide a more efficient and equitable
llocation of health care resources in cardiovascular imaging.
he ultimate objective of appropriateness criteria is to
mprove patient care and health outcomes in a cost-effective
anner but is not intended to ignore the acknowledged
mbiguity and nuance intrinsic to clinical decision making.
ocal parameters, such as the availability or quality of
quipment or personnel, may influence the selection of
ppropriate imaging procedures. Thus, appropriateness cri-
eria should not be considered substitutes for sound clinical
udgment and practice experience.
Each Appropriateness Criteria Technical Panel is asked
o assess whether the use of the test for each indication is
ppropriate, uncertain, or inappropriate; and the following
efinition of appropriateness is provided:
An appropriate imaging study is one in which the expected
incremental information, combined with clinical judgment, exceeds
the expected negative consequences* by a sufficiently wide margin for
a specific indication that the procedure is generally considered
acceptable care and a reasonable approach for the indication.
he Technical Panel scores each indication as follows:
Score 7 to 9
Appropriate test for specific indication (test is generally
cceptable and is a reasonable approach for the indication).
Negative consequences include the risks of the procedure (i.e., radiation or contrastv
xposure) and the downstream impact of poor test performance such as delay in diagnosis
false negatives) or inappropriate diagnosis (false positives).Score 4 to 6
Uncertain for specific indication (test may be generally accept-
ble and may be a reasonable approach for the indication).
Uncertainty also implies that more research and/or patient infor-
ation is needed to classify the indication definitively.)
Score 1 to 3
Inappropriate test for that indication (test is not generally
cceptable and is not a reasonable approach for the indication).
The intermediate category has been discussed at length by
he Working Group. The contributors to this document
evelopment process acknowledge the diversity in clinical
pinion for particular patient presentations. The consensus of
he Working Group is that this intermediate level of appro-
riateness should be labeled “uncertain,” as critical patient or
esearch data are lacking and/or significant differences of
pinion exist among panel members regarding the value of the
ethod for that particular indication. It is anticipated that the
ppropriateness criteria reports will require frequent updates as
urther data are generated and information from the imple-
entation of the criteria is accumulated.
To prevent bias in the scoring process, the Technical Panel
eliberately included less than 50% representation by specialists
n the particular procedure under evaluation. Such specialists,
hile offering important clinical and technical insights into the
se of the procedure, might have a natural tendency to rate the
ndications within their specialty as more appropriate than
onspecialists. In addition, care was taken in providing objec-
ive, nonbiased information, including guidelines and key
eferences, to the Technical Panel.
It is with gratitude that we applaud the Technical Panel, a
rofessional group with a wide range of skills and insights, for
thoughtful and thorough deliberation of the merits of
TE/TEE for various indications. In addition to our thanks to
he Technical Panel for their dedicated work and review, we
ould like to offer special thanks to Robert Bonow, MD, Roberto
ang, MD, and Alan Pearlman, MD, for reviewing the draft
ndications; to Peggy Christiansen, the ACC librarian, for her
omprehensive literature searches; to Karen Caruth, who contin-
ally drove the process forward; and to ACCF Past President
amela S. Douglas, MD, MACC, for her insight and leadership.
Ralph G. Brindis, MD, MPH, FACC
Moderator, TTE/TEE Technical Panel
Chair, ACCF Appropriateness Criteria Working Group
ntroduction
his report addresses the appropriateness of transthoracic
nd transesophageal echocardiography (TTE/TEE). The
est characteristics of TTE and TEE have long been
ecognized as beneficial for defining cardiac structure and
unction. The relative ease of use and low risk of TTE/TEE
ompared to other cardiovascular imaging techniques pro-
ide many advantages, but also create opportunities for
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Appropriateness Criteria for Echocardiography July 10, 2007:187–204veruse and misuse in patients who may not obtain a
enefit, or who could have achieved a similar benefit
ithout the addition of the test. In particular, inappropriate
se may be costly and may prompt potentially harmful and
ostly downstream testing and treatment such as unwar-
anted coronary revascularization or unnecessary repeat
ollow-up. Concerns about inappropriate use exist among
hose who pay for these services and clinical leaders who
valuate the effectiveness of testing.
ethods
he range of potential indications for echocardiography is
arge. Thus, the indications included in this review are
urposefully broad, and comprise a wide array of cardiovas-
ular signs and symptoms as well as clinical judgment as to
he likelihood of cardiovascular abnormalities.
A detailed description of the methods used for ranking
he selected clinical indications is outlined in Appendix B
nd is also found more generally in a previous publication
itled, “ACCF Proposed Method for Evaluating the Ap-
ropriateness of Cardiovascular Imaging” (1). Briefly, this
rocess combines evidence-based medicine and practice
xperience by engaging a Technical Panel in a modified
elphi exercise.
eneral Assumptions for TTE/TEE
o prevent any nuances of interpretation, all indications
ere considered with the following important assumptions:
. All indications are assumed to be for adult patients (18
years of age or older).
. The test is performed and interpreted by a qualified
individual in a facility that is proficient in the imaging
technique (2–5).
The indications were constructed by echocardiography ex-
erts and modified based on discussions among the Working
roup, and feedback from independent reviewers and the
echnical Panel. Wherever possible, indications were mapped
o relevant clinical guidelines and key publications/references
Online Appendix B at http://www.acc.org).
The Technical Panel was comprised of clinician experts,
ome with backgrounds in cardiac imaging and others with
mpeccable credentials in general cardiovascular medicine,
ardiac surgery, emergency medicine, health services re-
earch, and health plan administration.*
bbreviations
PC  atrial premature contraction
S  aortic stenosis
SD  atrial septal defectFull details about the backgrounds of the members of the Technical Panel can be
ound in Appendix C.NP  B-type natriuretic peptide
OPD  chronic obstructive pulmonary disease
RT  cardiac resynchronization therapy
T  computed tomography
CG  electrocardiogram
V  left ventricular
I  myocardial infarction
R  mitral regurgitation
RI  magnetic resonance imaging
S  mitral stenosis
DA  patent ductus arteriosus
FO  patent foramen ovale
VC  premature ventricular contraction
PECT  single-photon emission computed tomography
VT  supraventricular tachycardia
IA  transient ischemic attack
SD  ventricular septal defect
T  ventricular tachycardia
TE/TEE Assumptions
imilar to the general assumptions listed previously, panel-
sts were asked to consider several assumptions specifically
or TTE/TEE, including:
. Panel members are to assume that a TTE examination
and report will include:
a. Use of a standard set of 2-dimensional views evalu-
ating the cardiac structures (6,7).
b. Use of 2-dimensional/M-mode imaging, color flow
Doppler, and spectral Doppler as they are generally
considered to be important elements of a comprehen-
sive TTE or TEE study (8–10). In evaluating the
appropriate indications, it is assumed that these ele-
ments would be part of the performance of the
comprehensive TTE or TEE examination.
c. Use of contrast is indicated and will be performed
when more than 2 contiguous segments of the left
ventricular endocardial border are not visualized (11).
. In general, it is assumed that TEE is appropriately used
as an adjunct or subsequent test to TTE when subopti-
mal TTE images preclude obtaining a diagnostic study.
The indications for which TEE may reasonably be the
test of first choice include, but are not limited to, the
indications presented in Table 7 of this document.
. In addition, it is reasonable to use TEE as a first test
when:
a. It is likely that suboptimal images will preclude
obtaining a diagnostic TTE study based on patient
characteristics alone (patient is intubated, recent post-
operative, intraprocedural study, severe chest wall
abnormalities, COPD, etc.); or when
b. visualization of certain structures seen best by TEE is
necessary to achieve the goals of the imaging test
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valve, atria, great vessels, and/or prosthetic valves.
. Intraoperative echocardiography is an important use of
this imaging modality. However, we explicitly did not
consider indications for its use as this is outside the scope
of this document.
. The range of potential indications for TTE/TEE is quite
large, particularly in comparison with other cardiovascu-
lar imaging tests. Thus, the indications are, at times,
purposefully broad to cover an array of cardiovascular
signs and symptoms as well as the ordering physician’s
best judgment as to the presence of cardiovascular
abnormalities. Additionally, there are likely clinical sce-
narios that are not covered by the current indications.
esults of Ratings
he final ratings for TTE and TEE (Tables 1 to 7) are
isted sequentially as obtained from the second-round rating
heets submitted by each panelist. Additionally, the indica-
ions are presented by appropriateness category (Tables 8 to
0). As required by ACCF appropriateness methodology
1), these ratings are adopted as is, without modification byDefinitions used by the Technical Panel can be found in
ppendix A. Supplemental tables, including documentation
f the mean absolute deviation from the median and level of
greement of rankings for each indication, can be found in
he Online Appendix A at http://www.acc.org.
For the 59 indications for TTE/TEE, 44 were found to
e appropriate, and 1 was uncertain. Fourteen of the
ndications were felt to be inappropriate reasons for the
erformance of a TTE/TEE study. The level of agreement
mong panelists as defined by RAND (12) was analyzed
ased on the BIOMED rule for a panel of 14 to 16. As
uch, agreement was defined as an indication where 4 or
ewer panelists rated outside the 3-point region containing
he median. Disagreement was defined as where the number
f panelists rating in each extreme region was at least 5. For
he indications labeled as appropriate, the panel showed
00% agreement, and for the indications labeled inappro-
riate, the panel was in agreement 78.6% of the time.
isagreement was not found for any of the indications.
TTE/TEE is a well-established test with many applicable
ndications. Two areas where TTE/TEE tests were gener-
lly considered reasonable were when conducting an initial
valuation of cardiac structure and ventricular function or
he initial evaluation of suspected valvular dysfunction. The
ajority of inappropriate indications were for indicationshe indication Writing Group or Working Group. that suggested annual testing.
TE/TEE Appropriateness Criteria (by Indication)
able 1. General Evaluation of Structure and Function
Indication
Appropriateness
Score (1–9)
Suspected Cardiac Etiology—General
1. Symptoms potentially due to suspected cardiac etiology, including but not limited to dyspnea, shortness of breath,
lightheadedness, syncope, TIA, cerebrovascular events
A (9)
2. Prior testing that is concerning for heart disease (i.e., chest X-ray, baseline scout images for stress echocardiogram,
ECG, elevation of serum BNP)
A (8)
Adult Congenital Heart Disease
3. Assessment of known or suspected adult congenital heart disease including anomalies of great vessels and cardiac
chambers and valves or suspected intracardiac shunt (ASD, VSD, PDA) either in unoperated patients or following
repair/operation
A (9)
4. Routine (yearly) evaluation of asymptomatic patients with corrected ASD, VSD, or PDA more than 1 year after
successful correction
I (3)
Arrhythmias
5. Patients who have isolated APC or PVC without other evidence of heart disease I (2)
6. Patients who have sustained or nonsustained SVT or VT A (8)
LV Function Evaluation
7. Evaluation of LV function with prior ventricular function evaluation within the past year with normal function (such as
prior echocardiogram, LV gram, SPECT, cardiac MRI) in patients in whom there has been no change in clinical
status
I (2)
8. Initial evaluation of LV function following acute MI A (9)
9. Re-evaluation of LV function following MI during recovery phase when results will guide therapy A (8)
Pulmonary Hypertension
10. Evaluation of known or suspected pulmonary hypertension including evaluation of right ventricular function and A (8)
estimated pulmonary artery pressure
TT
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Indication
Appropriateness
Score (1–9)
Hypotension or Hemodynamic Instability
11. Evaluation of hypotension or hemodynamic instability of uncertain or suspected cardiac etiology A (9)
Myocardial Ischemia/Infarction
12. Evaluation of acute chest pain with suspected myocardial ischemia in patients with nondiagnostic laboratory markers
and ECG and in whom a resting echocardiogram can be performed during pain
A (8)
13. Evaluation of suspected complication of myocardial ischemia/infarction, including but not limited to acute MR,
hypoxemia, abnormal chest X-ray, VSD, free-wall rupture/tamponade, shock, right ventricular involvement, heart
failure, or thrombus
A (9)
Respiratory Failure
14. Evaluation of respiratory failure with suspected cardiac etiology A (8)
Pulmonary Embolism
15. Initial evaluation of patient with suspected pulmonary embolism in order to establish diagnosis I (3)
16. Evaluation of patient with known or suspected acute pulmonary embolism to guide therapy (i.e., thrombectomy and
thrombolytics)
A (8)able 3. Evaluation of Valvular Function
Indication
Appropriateness
Score (1–9)
Murmur
17. Initial evaluation of murmur in patients for whom there is a reasonable suspicion of valvular or structural heart disease A (9)
Mitral Valve Prolapse
18. Initial evaluation of patient with suspected mitral valve prolapse A (9)
19. Routine (yearly) re-evaluation of mitral valve prolapse in patients with no or mild mitral regurgitation and no change in
clinical status
I (2)
Native Valvular Stenosis
20. Initial evaluation of known or suspected native valvular stenosis A (9)
21. Routine (yearly) re-evaluation of an asymptomatic patient with mild native AS or mild-moderate native MS and no
change in clinical status
I (2)
22. Routine (yearly) evaluation of an asymptomatic patient with severe native valvular stenosis A (7)
23. Re-evaluation of a patient with native valvular stenosis who has had a change in clinical status A (9)
Native Valvular Regurgitation
24. Initial evaluation of known or suspected native valvular regurgitation A (9)
25. Routine (yearly) re-evaluation of native valvular regurgitation in an asymptomatic patient with mild regurgitation, no
change in clinical status, and normal LV size
I (2)
26. Routine (yearly) re-evaluation of an asymptomatic patient with severe native valvular regurgitation with no change in
clinical status
A (8)
27. Re-evaluation of native valvular regurgitation in patients with a change in clinical status A (9)
Prosthetic Valve
28. Initial evaluation of prosthetic valve for establishment of baseline after placement A (9)
29. Routine (yearly) evaluation of a patient with a prosthetic valve in whom there is no suspicion of valvular dysfunction
and no change in clinical status
I (3)
30. Re-evaluation of patients with prosthetic valve with suspected dysfunction or thrombosis or a change in clinical status A (9)
Infective Endocarditis (Native or Prosthetic Valves)
31. Initial evaluation of suspected infective endocarditis (native and/or prosthetic valve) with positive blood cultures or a
new murmur
A (9)
32. Evaluation of native and/or prosthetic valves in patients with transient fever but without evidence of bacteremia or new
murmur
I (2)
33. Re-evaluation of infective endocarditis in patients with any of the following: virulent organism, severe hemodynamic
lesion, aortic involvement, persistent bacteremia, a change in clinical status, or symptomatic deterioration
A (9)
TT
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Indication
Appropriateness
Score (1–9)
34. Evaluation for cardiovascular source of embolic event (PFO/ASD, thrombus, neoplasm) A (8)
35. Evaluation of cardiac mass (suspected tumor or thrombus) A (9)
36. Evaluation of pericardial conditions including but not limited to pericardial mass, effusion, constrictive pericarditis,
effusive-constrictive conditions, patients post-cardiac surgery, or suspected pericardial tamponade
A (9)able 5. Evaluation of Aortic Disease
Indication
Appropriateness
Score (1–9)
37. Known or suspected Marfan disease for evaluation of proximal aortic root and/or mitral valve A (9)able 6. Evaluation of Hypertension, Heart Failure, or Cardiomyopathy
Indication
Appropriateness
Score (1–9)
Hypertension
38. Initial evaluation of suspected hypertensive heart disease A (8)
39. Routine evaluation of patients with systemic hypertension without suspected hypertensive heart disease I (3)
40. Re-evaluation of a patient with known hypertensive heart disease without a change in clinical status I (3)
Heart Failure
41. Initial evaluation of known or suspected heart failure (systolic or diastolic) A (9)
42. Routine (yearly) re-evaluation of patients with heart failure (systolic or diastolic) in whom there is no change in clinical
status
I (3)
43. Re-evaluation of known heart failure (systolic or diastolic) to guide therapy in a patient with a change in clinical status A (9)
Pacing Device Evaluation
44. Evaluation for dyssynchrony in a patient being considered for CRT A (8)
45. Patient with known implanted pacing device with symptoms possibly due to suboptimal pacing device settings to
re-evaluate for dyssynchrony and/or revision of pacing device settings
A (8)
Hypertrophic Cardiomyopathy
46. Initial evaluation of known or suspected hypertrophic cardiomyopathy A (9)
47. Routine (yearly) evaluation of hypertrophic cardiomyopathy in a patient with no change in clinical status I (3)
48. Re-evaluation of known hypertrophic cardiomyopathy in a patient with a change in clinical status to guide or evaluate
therapy
A (9)
Cardiomyopathy (Other)
49. Evaluation of suspected restrictive, infiltrative, or genetic cardiomyopathy A (9)
50. Screening study for structure and function in first-degree relatives of patients with inherited cardiomyopathy A (8)
Therapy With Cardiotoxic Agents
51. Baseline and serial re-evaluations in patients undergoing therapy with cardiotoxic agents A (8)
TT
*
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able 7. Use of Transesophageal Echocardiogram (TEE)
Indication
Appropriateness
Score (1–9)
Use of TEE as Initial Test*—Common Uses
52. Evaluation of suspected acute aortic pathology including dissection/transsection A (9)
53. Guidance during percutaneous noncoronary cardiac interventions including but not limited to septal ablation in patients
with hypertrophic cardiomyopathy, mitral valvuloplasty, PFO/ASD closure, radiofrequency ablation
A (9)
54. To determine mechanism of regurgitation and determine suitability of valve repair A (9)
55. To diagnose/manage endocarditis with a moderate or high pre-test probability (e.g., bacteremia, especially staph
bacteremia or fungemia)
A (9)
56. Persistent fever in patient with intracardiac device A (9)
Use of TEE as the Initial Test*—Common Uses—Atrial Fibrillation/Flutter
57. Evaluation of patient with atrial fibrillation/flutter to facilitate clinical decision-making with regards to anticoagulation
and/or cardioversion and/or radiofrequency ablation
A (9)
58. Evaluation of patient with atrial fibrillation/flutter for left atrial thrombus or spontaneous contrast when a decision has
been made to anticoagulate and not to perform cardioversion
I (3)
Use of TEE—Embolic Event
59. Evaluation for cardiovascular source of embolic event in a patient who has a normal TTE and normal ECG and no
history of atrial fibrillation/flutter
U (6)
In general, it is assumed that TEE is appropriately used as an adjunct or subsequent test to TTE when suboptimal TTE images preclude obtaining a diagnostic study. The indications for which TEE
ay reasonably be the test of first choice include, but are not limited to, the indications presented in the TEE table.
able 8. Appropriate Indications (Median Score 7–9)
Indication
Appropriateness
Score (1–9)
General Evaluation of Structure and Function—Suspected Cardiac Etiology—General
1. Symptoms potentially due to suspected cardiac etiology, including but not limited to dyspnea, shortness of breath,
lightheadedness, syncope, TIA, cerebrovascular events
A (9)
2. Prior testing that is concerning for heart disease (i.e., chest X-ray, baseline scout images for stress echocardiogram,
ECG, elevation of serum BNP)
A (8)
General Evaluation of Structure and Function—Adult Congenital Heart Disease
3. Assessment of known or suspected adult congenital heart disease including anomalies of great vessels and cardiac
chambers and valves, or suspected intracardiac shunt (ASD, VSD, PDA) either in unoperated patient or following
repair/operation
A (9)
General Evaluation of Structure and Function—Arrhythmias
6. Patients who have sustained or nonsustained SVT or VT A (8)
General Evaluation of Structure and Function—LV Function Evaluation
8. Initial evaluation of LV function following acute MI A (9)
9. Re-evaluation of LV function following MI during recovery phase when results will guide therapy A (8)
General Evaluation of Structure and Function—Pulmonary Hypertension
10. Evaluation of known or suspected pulmonary hypertension including evaluation of right ventricular function and
estimated pulmonary artery pressure
A (8)
Cardiovascular Evaluation in an Acute Setting—Hypotension or Hemodynamic Instability
11. Evaluation of hypotension or hemodynamic instability of uncertain or suspected cardiac etiology A (9)
Cardiovascular Evaluation in an Acute Setting—Myocardial Ischemia/Infarction
12. Evaluation of acute chest pain with suspected myocardial ischemia in patients with nondiagnostic laboratory markers
and ECG and in whom a resting echocardiogram can be performed during pain
A (8)
13. Evaluation of suspected complication of myocardial ischemia/infarction, including but not limited to acute mitral
regurgitation, hypoxemia, abnormal chest X-ray, VSD, free-wall rupture/tamponade, shock, right ventricular
involvement, heart failure, or thrombus
A (9)
Cardiovascular Evaluation in an Acute Setting—Respiratory Failure
14. Evaluation of respiratory failure with suspected cardiac etiology A (8)
Cardiovascular Evaluation in an Acute Setting—Pulmonary Embolism
16. Evaluation of patient with known or suspected acute pulmonary embolism to guide therapy (i.e., thrombectomy and A (8)
thrombolytics)
T195JACC Vol. 50, No. 2, 2007 Douglas et al.
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Indication
Appropriateness
Score (1–9)
Evaluation of Valvular Function—Murmur
17. Initial evaluation of murmur in patients for whom there is a reasonable suspicion of valvular or structural heart disease A (9)
Evaluation of Valvular Function—Mitral Valve Prolapse
18. Initial evaluation of patient with suspected mitral valve prolapse A (9)
Evaluation of Valvular Function—Native Valvular Stenosis
20. Initial evaluation of known or suspected native valvular stenosis A (9)
22. Routine (yearly) evaluation of an asymptomatic patient with severe native valvular stenosis A (7)
23. Re-evaluation of a patient with native valvular stenosis who has had a change in clinical status A (9)
Evaluation of Valvular Function—Native Valvular Regurgitation
24. Initial evaluation of known or suspected native valvular regurgitation A (9)
26. Routine (yearly) re-evaluation of an asymptomatic patient with severe native valvular regurgitation with no change in
clinical status
A (8)
27. Re-evaluation of native valvular regurgitation in patients with a change in clinical status A (9)
Evaluation of Valvular Function—Prosthetic Valve
28. Initial evaluation of prosthetic valve for establishment of baseline after placement A (9)
30. Re-evaluation of patients with prosthetic valve with suspected dysfunction or thrombosis or a change in clinical status A (9)
Evaluation of Valvular Function—Infective Endocarditis (Native or Prosthetic Valves)
31. Initial evaluation of suspected infective endocarditis (native and/or prosthetic valve) with positive blood cultures or a
new murmur
A (9)
33. Re-evaluation of infective endocarditis in patients with any of the following: virulent organism, severe hemodynamic
lesion, aortic involvement, persistent bacteremia, a change in clinical status, or symptomatic deterioration
A (9)
Evaluation of Intracardiac and Extracardiac Structures and Chambers
34. Evaluation for cardiovascular source of embolic event (PFO/ASD, thrombus, neoplasm) A (8)
35. Evaluation of cardiac mass (suspected tumor or thrombus) A (9)
36. Evaluation of pericardial conditions including but not limited to pericardial mass, effusion, constrictive pericarditis,
effusive-constrictive conditions, patients post-cardiac surgery, or suspected pericardial tamponade
A (9)
Evaluation of Aortic Disease
37. Known or suspected Marfan disease for evaluation of proximal aortic root and/or mitral valve A (9)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Hypertension
38. Initial evaluation of suspected hypertensive heart disease A (8)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Heart Failure
41. Initial evaluation of known or suspected heart failure (systolic or diastolic) A (9)
43. Re-evaluation of known heart failure (systolic or diastolic) to guide therapy in a patient with a change in clinical status A (9)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Pacing Device Evaluation
44. Evaluation for dyssynchrony in a patient being considered for CRT A (8)
45. Patient with known implanted pacing device with symptoms possibly due to suboptimal pacing device settings to
re-evaluate for dyssynchrony and/or revision of pacing device settings
A (8)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Hypertrophic Cardiomyopathy
46. Initial evaluation of known or suspected hypertrophic cardiomyopathy A (9)
48. Re-evaluation of known hypertrophic cardiomyopathy in a patient with a change in clinical status to guide or evaluate
therapy
A (9)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Cardiomyopathy (Other)
49. Evaluation of suspected restrictive, infiltrative, or genetic cardiomyopathy A (9)
50. Screening study for structure and function in first-degree relatives of patients with inherited cardiomyopathy A (8)
Evaluation of Hypertension, Heart Failure, or Cardiomyopathy—Therapy With Cardiotoxic Agents
51. Baseline and serial re-evaluations in patients undergoing therapy with cardiotoxic agents A (8)
Use of TEE as the Initial Test—Common Uses
52. Evaluation of suspected acute aortic pathology including dissection/transsection A (9)
53. Guidance during percutaneous noncoronary cardiac interventions including but not limited to septal ablation in patients
with hypertrophic cardiomyopathy, mitral valvuloplasty, PFO/ASD closure, radiofrequency ablation
A (9)
54. To determine mechanism of regurgitation and determine suitability of valve repair A (9)
55. To diagnose/manage endocarditis with a moderate or high pre-test probability (e.g., bacteremia, especially staph
bacteremia or fungemia)
A (9)
56. Persistent fever in patient with intracardiac device A (9)
Use of TEE as the Initial Test—Common Uses—Atrial Fibrillation/Flutter
57. Evaluation of patient with atrial fibrillation/flutter to facilitate clinical decision-making with regards to anticoagulation
and/or cardioversion and/or radiofrequency ablation
A (9)
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he appropriateness criteria in this report provide an estimate
f the reasonableness of the use of TTE/TEE for the particular
linical scenario presented in each of the 59 indications
onsidered. They are expected to be useful for clinicians, health
are facilities, and third-party payers engaged in the delivery of
ardiovascular imaging. Experience with already published
ppropriateness criteria for SPECT nuclear imaging (13) and
able 9. Uncertain Indications (Median Score 4–6)
Indication
Use of TEE as the In
59. Evaluation for cardiovascular source of embolic event in a pa
history of atrial fibrillation/flutter
able 10. Inappropriate Indications (Median Score 1–3)
Indication
General Evaluation of Structure and F
4. Routine (yearly) evaluation of asymptomatic patients with co
successful correction
General Evaluation of Struc
5. Patients who have isolated APC or PVC without other eviden
General Evaluation of Structure a
7. Evaluation of LV function with prior ventricular function evalu
prior echocardiogram, LV gram, SPECT, cardiac MRI) in pa
status
Cardiovascular Evaluation in an
15. Initial evaluation of patient with suspected pulmonary embol
Evaluation of Valvular Fu
19. Routine (yearly) re-evaluation of mitral valve prolapse in pati
Evaluation of Valvular Func
21. Routine (yearly) re-evaluation of an asymptomatic patient wi
change in clinical status
Evaluation of Valvular Functi
25. Routine (yearly) re-evaluation of native valvular regurgitation
change in clinical status, and normal LV size
Evaluation of Valvular
29. Routine (yearly) evaluation of a patient with a prosthetic valv
and no change in clinical status
Evaluation of Valvular Function—Infectiv
32. Evaluation of native and/or prosthetic valves in patients with
murmur
Evaluation of Hypertension, Heart F
39. Routine evaluation of patients with systemic hypertension w
40. Re-evaluation of a patient with known hypertensive heart dis
Evaluation of Hypertension, Heart F
42. Routine (yearly) re-evaluation of patients with heart failure (s
status
Evaluation of Hypertension, Heart Failure, o
47. Routine (yearly) evaluation of hypertrophic cardiomyopathy i
Use of TEE as the Initial Test—Co
58. Evaluation of a patient with atrial fibrillation/flutter for left a
has been made to anticoagulate and not to perform cardardiac CT and MR (14) has shown great value across a broad iange of situations, guiding care of individual patients, educat-
ng caregivers, and informing policy decisions regarding reim-
ursement for cardiovascular imaging.
Appropriateness criteria represent the first component of
he chain of quality recommended for cardiovascular imag-
ng (15). After ensuring proper test selection, the achieve-
ent of quality in imaging includes adherence to best
ractices in image acquisition, image interpretation, and
esults communication, as well as incorporation of findings
Appropriateness
Score (1–9)
est—Embolic Event
who has a normal TTE and normal ECG and no U (6)
Appropriateness
Score (1–9)
on—Adult Congenital Heart Disease
d ASD, VSD, or PDA more than 1 year after I (3)
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eart disease I (2)
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within the past year with normal function (such as
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Uses—Atrial Fibrillation/Flutter
rombus or spontaneous contrast when a decision
ion
I (3)itial T
tientuncti
rrecte
ture a
ce of h
nd Fu
ation
tients
Acute
ism in
nction
ents w
tion—
th mil
on—N
in an
Funct
e in w
e End
trans
ailure,
ithout
ease w
ailure,
ystolic
r Card
n a pa
mmon
trial th
ioversnto clinical care. All components are important for optimal
p
T
r
s
c
a
a
a
f
h
d
p
p
e
c
m
i
c
u
f
r
v
p
t
b
t
i
p
b
v
a
n
c
i
e
p
g
a
w
o
t
p
m
a
m
c
p
p
c
i
i
i
a
i
t
b
o
a
t
r
i
o
a
t
p
p
c
s
i
m
w
p
t
a
q
m
m
i
t
f
a
u
P
c
t
u
p
t
t
m
r
q
i
p
p
a
e
p
a
o
h
s
p
r
197JACC Vol. 50, No. 2, 2007 Douglas et al.
July 10, 2007:187–204 Appropriateness Criteria for Echocardiographyatient care, although not all are addressed in this report.
he development of appropriateness criteria and their
anking by the Technical Panel assumes that other quality
tandards are adequately met. It also is assumed that when
onsidering the appropriateness of ordering a repeat or
nnual test the prior image and report can be obtained and
re of sufficient quality as previously outlined.
Although the appropriateness ratings reflect the general
ssessment of when TTE or TEE may or may not be useful
or specific patient populations, physicians and other stake-
olders should understand the role of clinical judgment in
etermining whether to order a test for an individual
atient. For example, the rating of an indication as inap-
ropriate should not preclude a provider from performing
chocardiographic procedures when there are patient- and
ondition-specific data to support that decision. Indeed, this
ay be the correct clinical pathway if supported by mitigat-
ng characteristics of the patient. Likewise, uncertain indi-
ations often require individual physician judgment and
nderstanding of the patient to better determine the use-
ulness of a test for a particular scenario. As such, the
anking of an indication as uncertain (4–6) should not be
iewed as limiting the use of echocardiography for such
atients. Finally, there may be clinical situations in which
he use of echocardiography for an indication considered to
e appropriate does not always represent reasonable prac-
ice, such as for a patient in whom another diagnostic
maging test might be scheduled or has already been
erformed.
The indications contained in this report are purposefully
road to capture the range of situations in which clinicians find
alue in echocardiographic information. However, as with the
ppropriateness criteria for other imaging modalities, they are
ot exhaustive due to the complexity and number of potential
linical situations. Similarly, current disease-based guidelines
nclude additional recommendations concerning the use of
chocardiography that are not included in the set of indications
resented in this paper. For example, the chronic stable angina
uideline (16) includes a Class III recommendation discour-
ging the use of echocardiography for symptomatic patients
ith a normal ECG, no history of MI, and without symptoms
r signs suggestive of chronic heart failure. The recommenda-
ions of such guidelines remain a part of ACC/AHA clinical
olicy, and should continue to guide care. Additionally, there
ay be reasons that would preclude the application of the
ppropriateness criteria to a specific patient, and clinical judg-
ent should be used at all times in the application of these
riteria.
Echocardiography tests, like many imaging tests, may
rovide additional useful information beyond the primary
urpose outlined by the indication. The appropriateness
riteria for TTE/TEE were not developed to quantify the
ncremental information that could be obtained by perform-
ng the test for reasons beyond those stated in an individual
ndication. Thus, members of the Technical Panel were
sked specifically not to consider implicit or additional dnformation outside the scope of an individual indication in
heir rankings. As such, the entire list of indications should
e reviewed to assess the full range of potential reasons for
rdering an echocardiogram for an individual patient. In
ddition, panelists were asked not to consider comparisons
o other imaging procedures or other appropriateness crite-
ia documents while completing their rankings, but to
nstead consider the particular echocardiography test on its
wn merits. As such, the scores and conclusions about
ppropriateness also should not be directly compared with
he prior report for appropriateness for SPECT myocardial
erfusion imaging (13), cardiovascular computed tomogra-
hy, or cardiovascular magnetic resonance (14).
There are many potential applications for appropriateness
riteria. Clinicians could use the ratings as a decision
upport or educational tool when ordering a test or provid-
ng a referral to another qualified physician. The criteria also
ay be used as a discussion tool with a referring physician
ho has a suggested pattern of ordering tests for inappro-
riate indications. Facilities and payers may choose to use
he criteria either prospectively in the design of protocols
nd pre-authorization procedures, or retrospectively for
uality reports. It is hoped that payers will use this docu-
ent as the basis for their own strategies to ensure that their
embers receive quality, cost-effective cardiovascular care.
As outlined in the original methodology by ACCF (1), it
s expected that services performed for appropriate indica-
ions will receive reimbursement. In contrast, services per-
ormed for inappropriate indications will likely require
dditional documentation to justify payment because of
nique circumstances or the clinical profile of the patient.
ayers should note that the Technical Panel and clinical
ommunity do not consider uncertain indications as those
hat should not be performed or reimbursed. Rather, the
ncertain indications are those where the opinions of the
anel varied and the data may be conflicting. In many of
hese areas, additional research is clearly desirable. Indica-
ions with high clinical volume that are rated as uncertain
ay suggest areas for increased focus and research.
When used to assess performance, appropriateness crite-
ia should be used in conjunction with systems that support
uality improvement. Ordering forms containing essential
nformation for determining appropriateness along with
eriodic feedback reports to providers may help educate
roviders on their ordering patterns. Prospective pre-
uthorization procedures, if put in place, may be used most
ffectively once a retrospective review has identified a
attern of potential inappropriate use. Because the criteria
re based on current scientific evidence and the deliberations
f the Technical Panel, they can be used prospectively to
elp resolve future reimbursement cases or appeals but
hould not be applied retrospectively to cases completed
rior to issuance of this report.
The primary objective of this report is to provide guidance
egarding the perceived suitability of echocardiography for
iverse clinical scenarios. As with previous appropriateness
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Appropriateness Criteria for Echocardiography July 10, 2007:187–204riteria documents, consensus among the raters was desirable,
ut any attempt to achieve complete agreement within this
iverse panel would have been artificial and not necessarily of
linical value. Two rounds of ratings with lively discussion
etween the ratings did lead to some consensus among
anelists. However, further attempts to drive consensus would
ave diluted true differences in opinion among panelists and,
herefore, was not undertaken.
Future research analyzing patient outcomes utilizing
ndications rated appropriate would help ensure the equita-
le and efficient allocation of resources for diagnostic
tudies. Review of medically necessary care may also im-
rove the understanding of regional variations in imaging
tilization. Further exploration of the indications rated as
uncertain” will help generate the data required to further
efine the appropriateness of echocardiography. Finally, it
ill be necessary to periodically assess and update the
ndications and criteria as technology evolves and new data
nd field experience becomes available.
ppendix A: TTE/TEE Definitions
trial premature contraction: a depolarization of the atrium
hich occurs with a coupling interval shorter than that result-
ng from the intrinsic heart rhythm.
hest pain syndrome or anginal equivalent (acute): any
onstellation of acute symptoms that the physician feels may
epresent a complaint consistent with obstructive coronary
rtery disease. Examples of such symptoms include, but are
ot exclusive to, chest pain, chest tightness, burning, dys-
nea, shoulder pain, palpitations, syncope, breathlessness, and
aw pain.
linical status: clinically meaningful indicators of a speci-
ed condition, including signs, symptoms, physical exami-
ation, and/or functional status.
ntracardiac device: any pacing device or implantable
ardioverter-defibrillator including pacemakers and/or
RTs.
eft ventricular function (normal): greater than or equal
o 50% ejection fraction.
itral valve prolapse (suspected): the auscultatory find-
ngs in mitral valve prolapse, when present, may consist of a
lick or multiple clicks that move within systole with
hanges in LV dimensions and/or a late systolic or holosys-
olic murmur of MR.
itral valve prolapse: valve prolapse of 2 mm or more
bove the mitral annulus in the long-axis parasternal view
nd other views.
urmurs (reasonable suspicion): does not have the char-
cteristics of innocent murmurs. The characteristics of
nnocent murmurs in asymptomatic adults that have no
unctional significance include the following:
Grade 1 to 2 intensity at the left sternal border
a systolic ejection pattern tnormal intensity and splitting of the second heart sound
no other abnormal sounds or murmurs
no evidence of ventricular hypertrophy or dilatation, and
the absence of increased murmur intensity with the
Valsalva maneuver or with standing from a squatting
position.
Such murmurs are especially common in high-output
tates such as anemia and pregnancy. When the character-
stic features of individual murmurs are considered together
ith information obtained from the history and physical
xamination, the correct diagnosis can usually be estab-
ished.
ative valvular regurgitation (mild, moderate, severe):
ee Table 11. Classification of the Severity of Valve Disease
n Adults (17).
ative valvular stenosis (mild, moderate, severe): see
able 11. Classification of the Severity of Valve Disease in
dults (17).
acing device: any implanted cardiac device designed to pace
he contraction of the heart including CRT and traditional
acemakers, with or with implantable cardioverter-defibrillator
apability.
remature ventricular contraction: a depolarization of the
entricle that occurs with a coupling interval shorter than
hat resulting from the intrinsic heart rhythm.
upraventricular tachycardia: a tachycardia that emanates
rom or requires participation of supraventricular tissue.
hese tachycardias can be either persistent or paroxysmal.
Atrial tachycardias other than atrial fibrillation and flutter
AV node re-entry
AV re-entry
uspected cardiac etiology (concerning for structural
eart disease): reasonable clinical concern for structural
eart disease based on but not limited to findings on history,
hysical exam findings, or other prior test results.
entricular tachycardia: a cardiac arrhythmia of 3 or more
onsecutive complexes in duration emanating from the
entricles at a rate greater than 100 beats per min (cycle
ength less than 600 ms).
ppendix B: Methods
anel Selection
takeholders were given the opportunity to participate in
he appropriateness criteria process by submitting nominees
rom their organizations through a Call for Nominations
eleased in the summer of 2006. From this list of nominees,
he Working Group selected panel members to ensure an
ppropriate balance with respect to expertise in the specific
odality, referring physicians, academic versus private prac-ice, health services research, and specialty training.
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A. Left-sided valve disease
Indicator
Aortic Stenosis
ereveSetaredoMdliM
0.4nahtretaerG0.4–0.30.3nahtsseL)dnocesrepm(yticolevteJ
04nahtretaerG04–5252nahtsseL*)gHmm(tneidargnaeM
Valve area (cm2 0.1nahtsseL5.1–0.15.1nahtretaerG)
Valve area index (cm2 per m2) Less than 0.6
Mitral Stenosis
ereveSetaredoMdliM
01nahtretaerG01–55nahtsseL*)gHmm(tneidargnaeM
Pulmonary artery systolic pressure
(mm Hg)
05nahtretaerG05–0303nahtsseL
Valve area (cm2 0.1nahtsseL5.1–0.15.1nahtretaerG)
Aortic Regurgitation
ereveSetaredoMdliM
Qualitative
Angiographic grade 1 2 3–4
Color Doppler jet width Central jet, width less than 25%
of LVOT
Greater than mild but no signs of
severe AR
Central jet, width greater
than 65% LVOT
Doppler vena contracta width
(cm)
6.0nahtretaerG6.0–3.03.0nahtsseL
Quantitative (cath or echo)
06otlauqeronahtretaerG95–0303nahtsseL)taebreplm(emulovtnatigrugeR
05otlauqeronahtretaerG94–0303nahtsseL)%(noitcarftnatigrugeR
Regurgitant orifice area (cm2 otlauqeronahtretaerG92.0–01.001.0nahtsseL)
0.30
Additional essential criteria
Left ventricular size Increased
Mitral Regurgitation
ereveSetaredoMdliM
Qualitative
Angiographic grade 1 2 3–4
Color Doppler jet area Small, central jet (less than 4 cm2
or less than 20% LA area)
Signs of MR greater than mild present
but no criteria for severe MR
Vena contracta width greater
than 0.7 cm with large
central MR jet (area
greater than 40% of LA
area) or with a wall-
impinging jet of any size,
swirling in LA
Doppler vena contracta width
(cm)
otlauqeronahtretaerG96.0–3.03.0nahtsseL
0.70
Quantitative (cath or echo)
06otlauqeronahtretaerG95–0303nahtsseL)taebreplm(emulovtnatigrugeR
05otlauqeronahtretaerG94–0303nahtsseL)%(noitcarftnatigrugeR
Regurgitant orifice area (cm2 otlauqeronahtretaerG93.0–2.002.0nahtsseL)
0.40
Additional essential criteria
Left atrial size Enlarged
Left ventricular size Enlarged
citsiretcarahCesaesidevlavdedis-thgiR.B
Severe tricuspid stenosis: Valve area less than 1.0 cm2
Severe tricuspid regurgitation: Vena contracta width greater than 0.7 cm and systolic flow reversal in hepatic veins
Severe pulmonic stenosis: Jet velocity greater than 4 m per second or maximum gradient greater than 60 mm Hg
Severe pulmonic regurgitation: Color jet fills outflow tract; dense continuous wave Doppler signal with a steep deceleration slope
*Valve gradients are flow dependent and when used as estimates of severity of valve stenosis should be assessed with knowledge of cardiac output or forward flow across the valve.
Modified from the Journal of the American College of Cardiology, 48, Bonow RO, Carabello BA, Chatterjee K, et al.  ACC/AHA 2006 guidelines for the management of patients 
with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the
1998 Guidelines for the Management of Patients With Valvular Heart Disease) (17).  
AR = aortic regurgitation; cath = catheterization; echo = echocardiography; LA = left atrial/atrium; LVOT = left ventricular outflow tract; MR = mitral regurgitation.
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he process for creating a robust set of indications involved
onsulting current literature and previously published guide-
ines and clinical policy statements. The indications capture the
ajority of scenarios faced by cardiologists or referring physi-
ians, but are not meant to be inclusive of all potential
ndications for which echocardiography studies may be per-
ormed. Review was done by the Working Group, including
dditional comments from external reviewers. As a result of the
eeting of the Technical Panel prior to the second round of
ating, a number of the indications were clarified and modified.
final set of indications comprised the list of possible clinical
cenarios that were rated for appropriateness by the panelists
nd compiled for this report.
ating Process
he Technical Panel was instructed to follow the process
utlined in the article previously published by the College
itled, “ACCF Proposed Method for Evaluating the Appro-
riateness of Cardiovascular Imaging” (1). The appropriateness
ethod combines expert clinical judgment with the scientific
iterature in evaluating the benefits and risks of medical
rocedures. Each panel member has equal weight in producing
he final result for the set of indications they are asked to rate,
nd the method does not force consensus.
The rating process includes a modified Delphi process
nvolving 2 rounds of ratings and an intervening face-to-
ace meeting. At the face-to-face meeting, each panelist
eceived a personalized rating form that indicated his/her
ating for each indication and the distribution of de-
dentified ratings of other members of the panel. In addi-
ion, the moderator received a summary rating form with
imilar information (including panelist identification), along
ith other statistics that measured the level of agreement
mong panel members. A measure of the level of disagree-
ent was applied to each score after both the first and
econd round scoring was completed. This project employed
he BIOMED Concerted Action on Appropriateness def-
nition for a panel size of 14 to 16. As defined in the
AND/UCLA manual (12) upon which the ACCF ratings
ethod is based, the BIOMED rule for agreement () is
hat no more than 4 panelists rate the indication outside the
-point region containing the median; for disagreement
), at least 5 panelists rate in each extreme rating region
i.e., 1 to 3 and 7 to 9). Measures of agreement and the
ispersion of ratings (mean absolute deviation from the
edian) may highlight areas where definitions are not clear
r ratings are inconsistent, where panelist perceptions of the
average” patient may differ, or where various specialty
roups or individual panelists may have differences of
linical opinion. In cases of obvious disagreement or outlier
cores, the indication was highlighted in a summary table
nd identification of the outlier raters brought to the
ttention of the moderator. This information was used by
he moderator to guide the panel’s discussion. Selationships With Industry
he College and its partnering organizations rigorously avoid
ny actual, perceived, or potential conflicts of interest that
ight arise as a result of an outside relationship or personal
nterest of a member of the Technical Panel. Specifically, all
anelists are asked to provide disclosure statements of all
elationships that might be perceived as real or potential
onflicts of interest. These statements were reviewed by the
ppropriateness Criteria Working Group, discussed with all
embers of the Technical Panel at the face-to-face meeting,
nd updated and reviewed as necessary. A table of disclosures
y each Technical Panel and Oversight Working Group
ember can be found in Appendix D.
iterature Review
he Technical Panel members were asked to refer to the
elevant guidelines for a summary of the relevant literature,
uideline recommendation tables, and reference lists provided
or each indication table when completing their ratings (Online
ppendix B at http://www.acc.org). Lastly, they were provided
eb links to the previously published materials pertaining to
he appropriateness criteria work (1,13,14).
ppendix C: ACCF Appropriateness Criteria
orking Group and Technical Panels
chocardiography Writing Group
amela S. Douglas, MD, MACC, FAHA, FASE: Lead
uthor, Appropriateness Criteria for Echocardiography—
ast President, ACC; Past President ASE; and Ursula
eller Professor of Research in Cardiovascular Diseases and
hief, Cardiovascular Disease, Duke University Medical
enter, Durham, NC
Bijoy Khandheria, MD, FACC, FASE—Profes-
or of Medicine and Chair, Division of Cardiovascular
isease, Mayo Clinic, Scottsdale, AZ
Raymond F. Stainback, MD, FACC, FASE—Medical
irector, Noninvasive Cardiac Imaging and Adult Echo-
ardiography, Texas Heart Institute at St. Luke’s Episcopal
ospital; Assistant Professor of Medicine (Clinical), Baylor
ollege of Medicine; Partner, Hall-Garcia Cardiology As-
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Neil J. Weissman, MD, FACC, FAHA, FASE—
rofessor of Medicine, Georgetown University Medical
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linical Professor of Medicine, University of California at
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ion of Cardiology, Duke University Medical Center,
urham, NC
Bijoy Khandheria, MD, FACC, FASE: Writing Group
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